Holm–Bonferroni method

Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease

Retrieved on: 
Tuesday, January 24, 2023
Disease, Thrombosis, Journal, Infection, Food, Rest, Chronic kidney disease, HUMA, Quality of life, PAD, Research, Sale, HAV, Patient, Pomeranian Medical University in Szczecin, Amputation, Holm–Bonferroni method, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, General surgery, Tissue, Pain, Pharmaceutical industry

DURHAM, N.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced the publication of “6-Year Outcomes of a Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass,” in the Journal of Vascular Surgery – Vascular Science. The publication describes the long-term analysis of the Company’s Phase 2 clinical trial evaluating the bioengineered HAV as a conduit in patients with symptomatic peripheral artery disease (PAD). The researchers concluded that “the infection-resistant, off-the-shelf human acellular vessel could provide a durable alternative conduit in the arterial circuit setting, to restore lower extremity blood supply in patients with peripheral artery disease.”

Key Points: 
  • The publication describes the long-term analysis of the Company’s Phase 2 clinical trial evaluating the bioengineered HAV as a conduit in patients with symptomatic peripheral artery disease (PAD).
  • No patients reported pain at rest or ischemic ulcers on the affected legs.
  • “Key findings of this publication show that the HAV was durable and performed well in a medically complex patient cohort for long-term treatment of PAD.
  • The HAV is an investigational product and has not been approved for sale by the U.S. Food and Drug Administration or any international regulatory agency.

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Retrieved on: 
Wednesday, November 30, 2022
Autoimmune disease, Degenerative disease, Holm–Bonferroni method, MD–PhD, Science, Transplant, Immune system, Infection, University, Cell, Graft-versus-host disease, Immunosuppression, Therapy, Patient, Organ transplantation, Donation, Plasma protein binding, University of Basel, Inflammation, Autoimmunity, Boehringer Ingelheim, MD, VC, Biozentrum University of Basel, Education, Vaccination, Cancer, Death, CSO, Research, Subclinical infection, Quality of life, Biology, Survival, Woman, South African Class ES, Pharmaceutical industry, Vaccine

The Company also announced that it has appointed Dr Ulf Grawunder to its Board of Directors.

Key Points: 
  • The Company also announced that it has appointed Dr Ulf Grawunder to its Board of Directors.
  • NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, Switzerland and is committed to creating tomorrow's safe immunotherapies by leveraging a novel targeted approach in T cell immunology.
  • We have recently bolstered our strong scientific expertise with biopharmaceutical entrepreneurial experience, and are now well placed for the next exciting growth stage.
  • NXI Therapeutics is developing modulators of the coronin 1 signaling pathway for the induction of highly selective immunosuppression without affecting broader defences against infectious diseases.

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Retrieved on: 
Wednesday, November 30, 2022
Autoimmune disease, Degenerative disease, Holm–Bonferroni method, MD–PhD, Science, Transplant, Immune system, Infection, University, Cell, Graft-versus-host disease, Immunosuppression, Therapy, Patient, Organ transplantation, Donation, Plasma protein binding, University of Basel, Inflammation, Autoimmunity, Boehringer Ingelheim, MD, VC, Biozentrum University of Basel, Education, Vaccination, Cancer, Death, CSO, Research, Subclinical infection, Quality of life, Biology, Survival, Woman, South African Class ES, Pharmaceutical industry, Vaccine

The Company also announced that it has appointed Dr Ulf Grawunder to its Board of Directors.

Key Points: 
  • The Company also announced that it has appointed Dr Ulf Grawunder to its Board of Directors.
  • NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, Switzerland and is committed to creating tomorrow's safe immunotherapies by leveraging a novel targeted approach in T cell immunology.
  • We have recently bolstered our strong scientific expertise with biopharmaceutical entrepreneurial experience, and are now well placed for the next exciting growth stage.
  • NXI Therapeutics is developing modulators of the coronin 1 signaling pathway for the induction of highly selective immunosuppression without affecting broader defences against infectious diseases.

Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
Clinical trial, CAR, Federal Reserve Board of Governors, HVG, Multiple myeloma, Persephone Borrow, ASH, Cancer, Security (finance), RRMM, Webcast, Investment, ORR, ADSS, Conference, Research, Lymphoid leukemia, Graft-versus-host disease, American Society for Investigative Pathology, EHA, Holm–Bonferroni method, SMART, Annual report, T cell, BCMA, IND, RMB, Gene editing, B-ALL, TME, IIT, MRD, Graceling, Translation, HLA, SAN, Patient, CD19, Pharmaceutical industry, Vaccine, Medical device, Medical imaging, Mobile phone, Cryptocurrency, Broadcasting, Renminbi

ET today

Key Points: 
  • ET today
    SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell or Company), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported third quarter unaudited financial results for the period ended September 30, 2022, and provided corporate updates.
  • First clinical data from ongoing IIT evaluating GC012F in NDMM patients to be presented as oral session at ASH 2022.
  • On track to submit the IND applications in the U.S. and China in the fourth quarter 2022 to evaluate GC012F for the treatment of RRMM.
  • Gracell specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise.

North America Human Leukocyte Antigen Testing Market Report 2022: Rising Government Funding for Organ Donation Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, November 18, 2022
Biotechnology, General Health, Health, Prevalence, Arrest, Transplant, Holm–Bonferroni method, Organ transplantation, Organ, Hlas, Protein, OPTN, Manifest and latent functions and dysfunctions, DCD, Conditional sentence, COVID-19, HLA, Kidney failure, Patient, Vaccine, Dentistry

The "North America Human Leukocyte Antigen Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and service, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Human Leukocyte Antigen Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and service, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.
  • Human leukocyte antigens (HLAs) are specialized proteins present on all cell surfaces of the human body except red blood cells.
  • The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing.
  • This factor is likely to drive the north america human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.

Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition

Retrieved on: 
Thursday, November 3, 2022
Haematopoietic system, Lymphatic system, Private Securities Litigation Reform Act, DNA, Baylor College of Medicine, Hodgkin lymphoma, Society, Clinical Lymphoma, Myeloma & Leukemia, PRIME, FDA, Marketing, Graft-versus-host disease, Clinical trial, MD Anderson Cancer Center, Hematological Cancer Research Investment and Education Act, Department, Company, Neoplasm, 2021 Essex County Council election, GLOBE, Trial of the century, Ernest, ASH, Plasma, Epstein–Barr virus, CEO, Gene therapy, Cancer, PD, GVHD, Research, European Medicines Agency, Baylor University, Center for Cell and Gene Therapy, Relapse, Holm–Bonferroni method, TT11, Stanford University, Cell, Safety, Therapy, CD30, Risk, Center, CHL, Pharmaceutical industry, Vaccine, Patient, Doctor of Philosophy

TT11X, Tessas allogeneic off-the-shelf cell therapy, is based on Tessas proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.

Key Points: 
  • TT11X, Tessas allogeneic off-the-shelf cell therapy, is based on Tessas proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
  • An abstract highlighting updated data from the ongoing Phase 1/2 study of TT11X (BESTA) in CD30-positive lymphomas will be featured in an oral podium presentation at ASH 2022.
  • We are honored that ASH has accepted three abstracts involving Tessas autologous and allogeneic CD30.CAR-T therapies, including two oral podium presentations, at its prestigious annual meeting, stated Thomas Willemsen, President and CEO of Tessa Therapeutics.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Retrieved on: 
Friday, November 4, 2022
Holm–Bonferroni method, Subclinical infection, Immune tolerance, Ageing, Asthma, Infection, Chronic kidney disease, DFU, Idiopathic pulmonary fibrosis, Pakistan Library Automation Group, Ethics, Internal medicine, Cytokine release syndrome, FDA, Safety, Incidence, ASX, Potency (pharmacology), Sepsis, Ulcer, Therapy, Leiden University Medical Center, Stem cell, Graft-versus-host disease, Acute respiratory distress syndrome, Transplant, Microsoft, Kidney transplantation, Regenerative medicine, US, MCA, Clinical trial, LUMC, MSC, Risk, Efficacy, Kidney, Survival, Patient, Osteoarthritis, Cancer, Department, Dialysis, Pharmaceutical industry, Dentistry

MELBOURNE, Australia, Nov. 4, 2022 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.

Key Points: 
  • Kidney transplantation is life-saving in patients with chronic renal failure and frees the patient from the need for dialysis.
  • The clinical trial, entitled the "Safety and Efficacy of iPSC-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients - the Nereid Study", will be led by Prof.
  • "This exciting new collaboration follows very promising clinical trial data with MSCs published by Professor Rabelink[1] and our own published pre-clinical data[2] in organ transplant rejection.
  • The consistency and potency of Cynata's unique iPSC-derived Cymerus MSCs make them an ideal candidate for this clinical trial."

Fountain Life Appoints Rakesh M. Suri, M.D., D.Phil., as President and Chief Medical Officer

Retrieved on: 
Thursday, October 13, 2022
Physician, Health, Editorial board, LinkedIn, Magdalen College, Oxford, Disease, Mayo Clinic, Queen's University, Life, Holm–Bonferroni method, American Board of Commissioners for Foreign Missions, The Journal of Thoracic and Cardiovascular Surgery, General surgery, Family, Longevity, Research, Instagram, American Board of Thoracic Surgery, Division, Queen, Facebook, Technology, Cancer, University, Cleveland, CEO, Cleveland Clinic, Journal, Artificial intelligence, Mayo College, Tesco international operations, FDA, Cardiothoracic surgery, Harvard Business School, Pharmaceutical industry

NAPLES, Fla., Oct. 13, 2022 /PRNewswire/ -- Fountain Life, a preventative health and longevity company committed to transforming global healthcare from reactive to proactive, today announced the appointment of Rakesh M. Suri, M.D., D.Phil., as the company's first President and Chief Medical Officer. Dr. Suri is an accomplished cardiac surgeon and prior executive leader at the Cleveland Clinic. In this new role, he will focus on the domestic and global expansion of Fountain Life's operations, including the establishment of partnerships with payers, community developers, corporate entities and wellness-oriented businesses. The mission of Fountain Life is to bring state-of-the-art diagnostics to detect disease early and to optimize and track the health of members in an experience-focused, technology-enabled and provider-led medical setting.

Key Points: 
  • The mission of Fountain Life is to bring state-of-the-art diagnostics to detect disease early and to optimize and track the health of members in an experience-focused, technology-enabled and provider-led medical setting.
  • "Fountain Life is a growing company that aims to transform healthcare through innovative data-driven technologies that help diagnose illnesses at their earliest stages," said William Kapp, M.D., Fountain Life's CEO and co-founder.
  • Before joining Fountain Life, Dr. Suri was President of International Operations and a practicing cardiothoracic surgeon at Cleveland Clinic in Ohio.
  • Fountain Life brings together the world's most renowned scientists and physicians to boost longevity and performance putting health back in healthcare.

Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery

Retrieved on: 
Thursday, September 29, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, Health, Clinical Trials, Endothelium, Holm–Bonferroni method, Safety, Transplant, Risk, SynCo Bio Partners, Cell proliferation, Florida State University, Therapy, Cornea, Severe cognitive impairment, Patient, Clinical trial, Corneal transplantation, Eye, CEO, Technology, FGF1, Fibroblast, Fuchs' dystrophy, DSO, Aqueous humour, CED, Disease, Immunosuppression, Pharmaceutical industry

Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD).

Key Points: 
  • Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD).
  • Presented at the World Cornea Congress 2022, data from the Phase 2 STORM trial examined if treatment with the investigational agent TTHX1114 led to faster vision recovery in patients undergoing a Descemet Stripping Only (DSO) procedure.
  • Additionally, DSO is more accessible to the millions of people living with corneal diseases around the world.
  • For the millions of people with corneal endothelial disease, this has the potential to be a first-line pharmacological treatment option.

Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions

Retrieved on: 
Tuesday, September 27, 2022
Health, Surgery, Genetics, Clinical Trials, Cardiology, Biotechnology, Heart, Iron, ACR, Probability, Cardiology, Centers for Medicare & Medicaid Services, Holm–Bonferroni method, Precision medicine, Risk, Transplant, FDA, GEP, CMS, EPUB, Catheter, International Society for Heart and Lung Transplantation, Baylor University Medical Center, The New England Journal of Medicine, Infection, Patient, Trauma, CEO, Method, Pain, Annual report, Nasdaq, Anxiety, International Society, PMID, Caregiver, Mechanical, DNA, Ann Harrison (lung transplant recipient), SEC, Neck, Biopsy, Center for Medicare and Medicaid Innovation, Swelling, Groin, Pharmaceutical industry, Medical imaging, Dentistry, Medical device, MD

These real-world findings reiterate the value of using this non-invasive test in heart transplant patients.

Key Points: 
  • These real-world findings reiterate the value of using this non-invasive test in heart transplant patients.
  • Its great to have this reminder because often traditional biopsies are used when a less invasive test may be a much better option for many heart transplant patients.
  • CareDx non-invasive heart transplant solutions, including AlloSure and AlloMap, have made transplant surveillance a less painful experience for patients.
  • CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.